215 related articles for article (PubMed ID: 38203742)
1. New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment.
Haddad D; Dsouza VS; Al-Mulla F; Al Madhoun A
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203742
[TBL] [Abstract][Full Text] [Related]
2. Recent drug development of dorzagliatin, a new glucokinase activator, with the potential to treat Type 2 diabetes: A review study.
Jiang Y; Wang L; Dong Z; Xia B; Pang S
J Diabetes; 2024 Jun; 16(6):e13563. PubMed ID: 38783768
[TBL] [Abstract][Full Text] [Related]
3. Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments.
Toulis KA; Nirantharakumar K; Pourzitaki C; Barnett AH; Tahrani AA
Drugs; 2020 Apr; 80(5):467-475. PubMed ID: 32162273
[TBL] [Abstract][Full Text] [Related]
4. Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far.
Kaur U; Pathak BK; Meerashahib TJ; Krishna DVV; Chakrabarti SS
Clin Drug Investig; 2024 Apr; 44(4):223-250. PubMed ID: 38460077
[TBL] [Abstract][Full Text] [Related]
5. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
[TBL] [Abstract][Full Text] [Related]
6. Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2.
Li W; Zhang X; Sun Y; Liu Z
Pharmazie; 2020 Jun; 75(6):230-235. PubMed ID: 32539915
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.
Fujieda H; Kogami M; Sakairi M; Kato N; Makino M; Takahashi N; Miyazawa T; Harada S; Yamashita T
Eur J Med Chem; 2018 Aug; 156():269-294. PubMed ID: 30006171
[TBL] [Abstract][Full Text] [Related]
8. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?
Matschinsky FM
Trends Pharmacol Sci; 2013 Feb; 34(2):90-9. PubMed ID: 23305809
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of efficacy and safety of glucokinase activators-a systematic review and meta-analysis.
Yang W; Wu H; Cai X; Lin C; Jiao R; Ji L
Front Endocrinol (Lausanne); 2023; 14():1175198. PubMed ID: 37223016
[TBL] [Abstract][Full Text] [Related]
10. Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.
Grewal AS; Sekhon BS; Lather V
Mini Rev Med Chem; 2014; 14(7):585-602. PubMed ID: 25052034
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of glucokinase activators for type 2 diabetes mellitus therapy: a meta-analysis of double-blind randomized controlled trials.
Qu Y; Wang K; Lin S; Cao L; Xu Z
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):914-922. PubMed ID: 33577046
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review on glucokinase activators: Promising agents for the treatment of Type 2 diabetes.
Thilagavathi R; Hosseini-Zare MS; Malini M; Selvam C
Chem Biol Drug Des; 2022 Feb; 99(2):247-263. PubMed ID: 34714587
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of glucokinase activators for the treatment of type-2 diabetes mellitus: A meta-analysis.
Gao Q; Zhang W; Li T; Yang G; Zhu W; Chen N; Jin H
Medicine (Baltimore); 2021 Oct; 100(40):e27476. PubMed ID: 34622877
[TBL] [Abstract][Full Text] [Related]
14. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection.
Zhu XX; Zhu DL; Li XY; Li YL; Jin XW; Hu TX; Zhao Y; Li YG; Zhao GY; Ren S; Zhang Y; Ding YH; Chen L
Diabetes Obes Metab; 2018 Sep; 20(9):2113-2120. PubMed ID: 29707866
[TBL] [Abstract][Full Text] [Related]
15. TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes.
Egan A; Vella A
Expert Opin Investig Drugs; 2019 Sep; 28(9):741-747. PubMed ID: 31398075
[No Abstract] [Full Text] [Related]
16. Targeting human Glucokinase for the treatment of type 2 diabetes: an overview of allosteric Glucokinase activators.
Sharma P; Singh S; Sharma N; Singla D; Guarve K; Grewal AS
J Diabetes Metab Disord; 2022 Jun; 21(1):1129-1137. PubMed ID: 35673438
[TBL] [Abstract][Full Text] [Related]
17. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator.
Vella A; Freeman JLR; Dunn I; Keller K; Buse JB; Valcarce C
Sci Transl Med; 2019 Jan; 11(475):. PubMed ID: 30651321
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of novel dual glucokinase activator dorzagliatin in type-2 diabetes A meta-analysis.
Dutta D; Khandelwal D; Kumar M; Sharma M
Diabetes Metab Syndr; 2023 Jan; 17(1):102695. PubMed ID: 36566614
[TBL] [Abstract][Full Text] [Related]
19. Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists.
Ren Y; Li L; Wan L; Huang Y; Cao S
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):606-615. PubMed ID: 35067153
[TBL] [Abstract][Full Text] [Related]
20. Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour?
Rees MG; Gloyn AL
Br J Pharmacol; 2013 Jan; 168(2):335-8. PubMed ID: 22946641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
